Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Zhejiang Nhu Co's long-term debt to total assests ratio for the quarter that ended in Jun. 2026 was 0.07.
Zhejiang Nhu Co's long-term debt to total assets ratio
declined
from Jun. 2025 (0.10) to Jun. 2026 (0.07).
It may suggest that Zhejiang Nhu Co is progressively becoming less dependent on debt to grow their business.
Zhejiang Nhu Co (SZSE:002001) LT-Debt-to-Total-Asset Explanation
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
Zhejiang Nhu Co LT-Debt-to-Total-Asset Related Terms
Zhejiang Nhu Co LT-Debt-to-Total-Asset Historical Data
* Premium members only.
The historical data trend for Zhejiang Nhu Co's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Nhu Co (SZSE:002001) has a LT-Debt-to-Total-Asset of 0.07 as of Jun. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Zhejiang Nhu Co and its competitors.
Is Zhejiang Nhu Co's LT-Debt-to-Total-Asset too high?
Zhejiang Nhu Co's current LT-Debt-to-Total-Asset is 0.07. Overall, Zhejiang Nhu Co has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Nhu Co's LT-Debt-to-Total-Asset compare to ZTS?
Zhejiang Nhu Co's LT-Debt-to-Total-Asset of 0.07 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Zhejiang Nhu Co and its competitors. Zhejiang Nhu Co's current LT-Debt-to-Total-Asset is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Nhu Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Nhu Co (SZSE:002001) is currently considered Fairly Valued. The stock's GF Value™ is ¥28.59, compared to a current price of ¥26.58 — trading 7% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.07. Zhejiang Nhu Co's overall GF Score™ is 98/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Zhejiang Nhu Co (SZSE:002001), the current LT-Debt-to-Total-Asset is 0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Nhu Co (SZSE:002001) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Nhu Co stock appears to be undervalued.
The current stock price of ¥26.58 is trading 7% below its estimated GF Value™ of ¥28.59.
GuruFocus considers Zhejiang Nhu Co to be Fairly Valued.
Key valuation signals for SZSE:002001:
LT-Debt-to-Total-Asset: 0.07
GF Value™: ¥28.59 vs. price of ¥26.58 (7% below fair value)
No single metric tells the full story. See the SZSE:002001 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Nhu Co Ltd is a China-based company engaged in the manufacture and sales of pharmaceuticals, health protection products, pharmaceutical intermediates, fragrances, food additives, and feed additives. The company's active pharmaceutical ingredient products cover various areas such as Cardiovascular, Anti-AIDS, Anti-cancer, and Anti-bacterial, with key products such as Latamoxef Sodium, Flomoxef Sodium, Hydrochloride Moxifloxacin, Artemisinin series, Calcium Keto acid series, Vitamin A/E/D3, and coenzyme Q10, and others. The other business areas are Aroma chemicals, Polymers, and Nutrition. The organization markets its products in China and internationally.
98GF Score
Get the complete analysis for SZSE:002001
LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:002001 has been successfully added to your 
